Z
Z

Zalando

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

European shares notch fourth straight record high on earnings strength

* Novo Nordisk among top boosts * Zalando, Adidas knock down retail sector * Mining stocks down on Chinese demand fears * BoE outlines plans for reducing stimulus By Sruthi Shankar and Ambar Warrick Aug 5 (Reuters) - European stocks ended at record highs on Thursday, as strong results from Novo Nordisk and Siemens helped outweigh weak mining stocks
A
B
B
E
S
Z
G
E
F
U

Take Five: Jobs, crackdowns and a fork

(Updates China entry with PMI readings, link) July 30 (Reuters) - 1/ OUT OF SURPRISES? Is this year's sharp U.S. growth rebound losing momentum? A raft of economic data due in the world's biggest economy will provide clues. U.S. non-farm payrolls on Aug. 6 will offer a snapshot of July hiring. Economists polled by Reuters forecast the economy added
B
C
C
C
H
N
S
S
Z
I

Take Five: Jobs, crackdowns and a fork

July 30 (Reuters) - 1/ OUT OF SURPRISES? Is this year's sharp U.S. growth rebound losing momentum? A raft of economic data due in the world's biggest economy will provide clues. U.S. non-farm payrolls on Aug. 6 will offer a snapshot of July hiring. Economists polled by Reuters forecast the economy added 926,000 jobs in July after June's forecast-be
B
C
C
C
H
N
S
S
Z
I

Fashion e-tailer About You eyes 4 bln euro valuation in Frankfurt listing

(Corrects to listing via a private placement, not an initial public offering) BERLIN, June 8 (Reuters) - German fashion e-tailer About You set a price range of 21 to 26 euros per share on Tuesday for its stock market listing, putting a prospective valuation of around 4 billion euros ($4.9 billion) on the business. The Hamburg startup will sell new
S
S
Z

European stocks end flat between Asia worries, British re-opening cheer

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * Asia restrictions, China data weigh * Kinnevik jumps to top of STOXX 600 * Spain's Telefonica gains as it seeks buyers for delivery arm * Sanofi, GSK gain as COVID-19 vaccine shows immune response (Updates with market close) By Shashank Na
E
G
K
S
T
Z
G
E
F
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.